Navigation Links
Hospitalization Rates for Coronary Artery Disease Decline in the,U.S.

EVANSTON, Ill., March 20, 2007 /PRNewswire/ -- Treatment of coronary artery disease (CAD) appears to be shifting away from the inpatient setting, according to a study published today in The American Journal of Cardiology.

U.S. hospitalization rates for heart attacks (acute myocardial infarctions) declined 10.6 percent from 2002 to 2005, possibly due to broader use of preventive treatments such as statin drugs and aspirin, as well as declines in risk factors like smoking.

The study is a collaboration between researchers from the University of Michigan Medical School and Solucient, part of Thomson Healthcare, a leading provider of information and solutions to improve the cost and quality of healthcare.

"Although there was an expectation that the aging U.S. population would cause an increased need for inpatient care of patients with cardiovascular disease, the reality is that changes in treatment may be causing a shift to the outpatient setting," said Janet Young, M.D., a senior scientist at Solucient. "This trend has important implications for hospitals and health systems and their allocation of resources."

    Researchers found that:

     - Hospitalizations for acute myocardial infarction (AMI) decreased

       steadily from 661,000 in 2002 to 591,000 in 2005 -- a decline from 309

       to 266 per 100,000 persons. This was driven by a decrease in the more

       severe transmural form of AMI from 118 to 87 per 100,000.

     - Hospitalization rates for coronary revascularization declined from 382

       to 358 per 100,000 persons from 2002 to 2005 -- largely due to a

       decrease in coronary artery bypass surgeries from 258,000 to 209,000

       per year.

     - During this period, inpatient use of less-invasive revascularization

       treatments known as percutaneous coronary interventions -- including

       the use of balloon angioplasty and stents administered via cardiac

       catheterization -- increased from 5
'"/>




Page: 1 2 3

Related medicine technology :

1. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
2. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
3. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
7. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
8. New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
9. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
10. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
11. Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hospitalization Rates for Coronary Artery Disease Decline the
(Date:10/13/2008)...r NIH funding advances study Study needed be...APOLIS, Oct. 13 /- Advanced Circulato...com ) announced today that it has received,an addi...nstitutes of,Health (NIH) to continue a study test...xperience cardiac arrest outside a hospital. Whatc...
(Date:10/13/2008)... Have Higher Sensitivity and Specificity, than Ot... the preferred test in all phases ... /- AT First Diagnostic LLC an,emergi...test kits, today,announced that a recent evaluatio...esearch of the FirstVue(TM) HBSAG Test, was releas...
(Date:10/12/2008)...d in Combination with Chemotherapy, FREMONT, Cali...Inc., a,development-stage pharmaceutical company d...RNAi)-based therapeutics, today announced that the...cacy of siRNA targeting,its proprietary target gen...e edition dated October 1, 2008. The paper, entitl...
(Date:10/10/2008)...- Diplomat Specialty,Pharmacy announc...mat,Specialty Pharmacy to be one of only three sit...py Optimization Study for Multiple Sclerosis (TOP ...to examine the benefits of a,specialty pharmacy th...and,patient outcomes. Targeted patient outcomes wi...
Breaking Medicine Technology:Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference 2438 1Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference 2438 2Danaher to Present at J P Morgan Healthcare Conference 2435 1Lack of Deep Sleep Raises Diabetes Risk 9038 1Lack of Deep Sleep Raises Diabetes Risk 9038 2Lack of Deep Sleep Raises Diabetes Risk 9038 3FDA approves additional dosage strengths of Vyvanse 9035 1FDA approves additional dosage strengths of Vyvanse 9035 2
...olecularly engineered,therapy selectively embeds a...tes tumors, inhibits metastasis, and prolongs surv...The University of,Texas M. D. Anderson Cancer Cent..."This vehicle, or vector, is so targeted and robus... used for therapy and,perhaps for imaging," notes ...
...ospinol,s (SP-233) Ability to Clear Brain,Plaque a...ion , In Vivo ,Proof of Concept, Study Proposes Di...que and Memory Recovery , LAS VEGAS, July 10, 2007.... (AMEX:LIV), a developer of innovative drugs,is ... (SP-233),efficacy in its ability to dramatically ...
Other Medicine Technology:Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 2Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 3Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 4Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 5Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 2Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 3
(Date:10/15/2008)... Will Educate Parents about Prescription,Drug Abus...mily Partnership (NFP),has designated Monday, Octo...g off the group,s 23rd annual Red Ribbon Week from...ents with action steps to prevent children,s,presc...million teens in the United States abuse,prescript...
(Date:10/14/2008)...4 /PRNewswire-USNewswire/ -- Kerby T.,Alvy, Ph.D.,...r for the,Improvement in North Hollywood (CICC), h... and Prevention (CDC) to serve as an expert to inf...or the prevention of child,maltreatment., CDC,s n...lationships,(SSNR) as the foundation for a unified...
(Date:10/14/2008)...ker Founder and CEO Andrew Levitt to showcase Heal... Somerville, MA (PRWEB) Octob... , the word-of-mouth marketing (WOM) firm for the ... announced that Andrew Levitt, Founder and CEO of ...Pharma and Health 2.0" at Health 2.0: User-Ge...
(Date:10/14/2008)...PRNewswire-FirstCall/ -- Warner Chilcott,Limited (... its third quarter,2008 financial results prior to... In addition to issuing a press release, the Comp... parties on Monday, November 10, 2008 at,8:00 AM (...e in the call,please dial (877) 856-1955 in the U...
Breaking Medicine News(10 mins):Health News:National Family Partnership Designates October 27th 'Lock Your Meds' Day 2Health News:National Family Partnership Designates October 27th 'Lock Your Meds' Day 3Health News:Los Angeles Psychologist to Help CDC Fight Child Abuse 2Health News:HealthTalker Founder and CEO Andrew Levitt to be Featured at 'Health 2.0: User-Generated Healthcare 2008' 2
...i bacteria outbreak in some vegetables revealed th...ffective in treating deadly //bacteria’s, growing ...have come up with an alternate solution - Edible c...eria apart from adding flavor. Edible coating for...
...e, one of the main ingredients in tooth whitening ...nd is safe to use–says an article //written by Dr....ased Tooth Whitening Products and it Relationship ...hed in Journal of Esthetic and Restorative Dentist...
...reat kidney cancer can prevent the development of ... lungs) in rodents, report researchers //from the ...f the American Heart Association, Nov. 12-15 in Ch...r this condition. 'We are excited about this fin...
...f migration season this winter, officials fear tha...irus H5N1 in Egypt and in other parts of the world...the necessary precautions well in advance on accou... flu virus might be even more deadly among fowl an...
Other Medicine News:Health News:Edible Food Coating Kills Bacteria And Adds Flavor 2Health News:Edible Food Coating Kills Bacteria And Adds Flavor 3Health News:Anti-Cancer Drug Shows Early Promise in Pulmonary Hypertension 2
Sabre 180, 230V, 50Hz is a powerful niche generator.
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c
Maddox rod and occluder
Long handle occluder - White
Medicine Products: